<DOC>
	<DOCNO>NCT00662675</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety oral pancrelipase MT treatment adult pediatric/adolescent cystic fibrosis ( CF ) patient clinical symptom exocrine pancreatic insufficiency ( EPI ) .</brief_summary>
	<brief_title>A Study Efficacy Tolerability Pancrelipase Microtablet ( MT ) Capsules Treatment Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency</brief_title>
	<detailed_description>This randomize , placebo-controlled , double-blind withdrawal , multicenter study evaluate effectiveness pancrelipase MT capsule compare placebo treatment adult ( &gt; 18 60 year age ) children/adolescent ( 7 &lt; 18 year age ) patient CF require pancreatic enzyme replacement therapy ( PERT ) control clinical symptom EPI steatorrhea ( excess fat feces ) . The study 3 phase : screening phase , open-label ( run-in ) phase , double-blind withdrawl phase . The study include screen phase approximately 28 day length . In screen phase , patient begin high-fat diet take pancrelipase MT10.5 MT21 capsule ( combination ) orally meal ( snack ) optimize digestion base clinical sign symptom . In open-label phase patient continue take optimal dose study drug . After minimum 3 day open-label treatment phase , inpatient 72-hour stool collection period fecal fat determination perform . Patients coefficient fat absorption ( COA ) -fat 80 % great complete least 6 day control high-fat diet eligible double-blind withdrawal phase study randomly assign receive placebo pancrelipase MT . After minimum 1 day double-blind treatment presence deteriorate clinical sign symptom , patient admit clinic begin second 72-hour inpatient stool collection period . Effectiveness evaluation perform throughout study consist stool collection determination COA-fat coefficient protein absorption ( COA-protein ) , stool diary , nutrition worksheet , Clinical Global Impression-Severity illness ( CGI-S ) , Clinical Global Impression-Change ( CGI-C ) , Global Assessment Change ( GAC ) scale . Signs symptom exhibit study monitor include presence absence diarrhea , abdominal pain , nausea , vomit , bloating , description stool change . Safety montitored study evaluate adverse event finding clinical laboratory test , vital sign measurement , physical examination . The study hypothesis study drug effective placebo measure change coefficient fat absorption ( COA-fat ) adult pediatric/adolescent patient EPI secondary CF . Pancrelipase MT10.5 MT21 capsule ( combination ) take orally meal ( snack ) within recommend range pancreatic enzyme therapy recommend CF Foundation maximum 10,000 lipase unit per kilogram [ kg ] per day . All patient take pancrelipase MT 6 day screen phase approximately 6 10 day open-label phase ; patient take pancrelipase MT placebo 4 7 day double-blind phase .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Malabsorption Syndromes</mesh_term>
	<mesh_term>Steatorrhea</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Have diagnosis CF document sweat chloride result ( &gt; 60 mmol/L ) require pancreatic enzyme replacement therapy ( PERT ) control clinical symptom EPI ( nausea , vomit , bloating , diarrhea , abdominal pain ) history excess fat feces Have documentation abnormal COAfat fecal elastase result &lt; 100 microgram fecal elastase/gram stool Must stable diet dose pancreatic enzyme supplementation provide satisfactory symptom control least past 1 month No extreme physical wasting loss weight muscle mass No severe , acute , chronic pulmonary disease unrelated complication CF No worsen pulmonary disease past 30 day No use drug know affect blood uric acid concentration ( e.g. , aspirin , diflunisal , allopurinol , probenecid , thiazide diuretic , phenylbutazone , sulfinpyrazone ) No know congenital ( present birth ) abnormalities gastrointestinal tract , heart , liver No distal intestinal obstruction syndrome ( DIOS )</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Exocrine pancreatic insufficiency</keyword>
	<keyword>Steatorrhea</keyword>
	<keyword>Malabsorption syndrome</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Adult</keyword>
	<keyword>Pancrelipase</keyword>
</DOC>